BY: SOFIA RESNICK AND KELCIE MOSELEY-MORRIS
MAY 18, 2023
America’s major medical institutions and drug policy scholars have roundly denounced as “pseudoscience” many of the claims brought by anti-abortion groups in a high-profile federal lawsuit asking the Food and Drug Administration to revoke its 23-year-old approval of mifepristone, one half of a two-drug regimen that has become the most common form of pregnancy termination post-Roe v. Wade.
But the appeals court’s three-judge panel that heard oral arguments Wednesday appeared to be persuaded not by the medical consensus in this case, but by some of the evidence brought forward by plaintiffs that consists largely of anecdotes, speculation, and cherry-picked studies brought by a handful of anti-abortion medical groups and doctors.
During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.
By ALICE MIRANDA OLLSTEIN and JOSH GERSTEIN
NEW ORLEANS — Three federal judges seemed poised to rule against the Biden administration in its efforts to preserve access to the abortion drug mifepristone.
During an occasionally combative, two-hour hearing Wednesday before a panel of the 5th Circuit Court of Appeals, the judges — all Republican appointees — grilled attorneys from the Justice Departments and Danco Laboratories, the pill’s manufacturer, who are battling to keep the drug available in the U.S.